Aurora Kinase Inhibition as a Novel Therapeutic Approach for the Treatment of Refractory Pediatric and Infant Leukemia

Simple item page
atmire.migration.oldid1918
dc.contributor.advisorNarendran, Aru
dc.contributor.authorJayanthan, Aarthi Anita
dc.date.accessioned2014-01-30T18:15:41Z
dc.date.available2014-03-15T07:00:20Z
dc.date.issued2014-01-30
dc.date.submitted2014en
dc.description.abstractLeukemia is the most common pediatric malignancy, constituting more than 30% of all childhood cancers. Although cure rates have improved greatly, approximately one in four children relapse and survival rates post relapse are very low. Given this, more effective and innovative therapeutic strategies are needed in order to improve prognosis. Aurora kinases, a family of serine/threonine kinases essential for the regulation of several mitotic processes, have been identified as potential targets for cancer therapeutics. Elevated expression of Aurora kinases has been determined in several malignancies and is associated with aberrant mitotic activity, aneuploidy, alterations in chromosomal structure and genome instability. Based on this, a panel of Aurora kinase inhibitors was tested against pediatric leukemia cells and demonstrated variable cytotoxicity, the induction of apoptosis and changes in Aurora kinase activity. The dual Aurora-A/B inhibitor AT9283 was selected for further investigation, as it also targets FLT3, Jak2 and c-Abl, which are important in leukemogenesis. AT9283 promoted a polyploid phenotype, inhibited pathways involved in growth and survival and displayed synergistic activity with novel and conventional therapeutics. Of these therapeutics, ABT-737, a B–cell lymphoma 2 inhibitor, and BI 6727, a Polo-like kinase inhibitor, promoted increased Aurora kinase phosphorylation. Similarly, Aurora kinase inhibition promoted increased Bcl-2 phosphorylation and increased Plk-1 expression and activity. Furthermore, ABT-737 and BI 6727 displayed synergistic activity with several Aurora kinase inhibitors. This study establishes the effects and potential mechanisms of Aurora kinase inhibition on pediatric leukemia in vitro both as single agents and in combination with novel and conventional therapeutics targeting pathways involved in apoptosis and mitosis.en_US
dc.identifier.citationJayanthan, A. A. (2014). Aurora Kinase Inhibition as a Novel Therapeutic Approach for the Treatment of Refractory Pediatric and Infant Leukemia (Doctoral thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25068en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/25068
dc.identifier.urihttp://hdl.handle.net/11023/1350
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectBiology--Cell
dc.subjectBiology--Molecular
dc.subjectOncology
dc.subject.classificationPediatricsen_US
dc.subject.classificationLeukemiaen_US
dc.subject.classificationTherapeuticsen_US
dc.titleAurora Kinase Inhibition as a Novel Therapeutic Approach for the Treatment of Refractory Pediatric and Infant Leukemia
dc.typedoctoral thesis
thesis.degree.disciplineMedical Science
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameDoctor of Philosophy (PhD)
ucalgary.item.requestcopytrue
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ucalgary_2014_jayanthan_aarthi.pdf
Size:
17.99 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.65 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Theses and Dissertations